Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zankiren SCHEMBL8352631 | 1.00 | REN (1.00) | REN | |
| Zankiren SCHEMBL8852548 | 1.00 | REN (1.00) | REN | |
| Zankiren SCHEMBL29885493 | 1.00 | REN (1.00) | REN | |
| Zankiren SCHEMBL7441825 | 1.00 | REN (1.00) | REN | |
| Zankiren SCHEMBL121553 | 0.99 | REN (0.99) | REN | |
| SCHEMBL14034941 | 0.88 | REN (0.78) | REN | |
| SCHEMBL14008235 | 0.88 | REN (0.78) | REN | |
| SCHEMBL8852557 | 0.83 | REN (0.71) | REN | |
| SCHEMBL8904006 | 0.81 | REN (0.69) | REN | |
| SCHEMBL30660206 | 0.80 | REN (0.67) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220370360-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-11-24 | — | — | US | claimed |
| WO-2022238734-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2022-11-17 | — | — | WO | claimed |
| US-20210401751-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development Inc. (US) | 2021-12-30 | — | — | US | claimed |
| WO-2005070406-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | claimed |
| EP-1531879-A1 | USE OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-05-25 | — | — | EP | claimed |
| EP-1507558-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC | Novartis AG (CH) | 2005-02-23 | — | — | EP | claimed |
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | PHARMACIA CORPORATION | 2004-12-30 | — | — | US | claimed |
| WO-2004100871-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A RENIN INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040087484-A1 | Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor | SAHOTA PRITAM SINGH (US) | 2004-05-06 | — | — | US | claimed |
| WO-2004002549-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-01-08 | — | — | WO | claimed |
| WO-2003097098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | claimed |
| EP-1353727-A2 | COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN ANTI-HYPERTENSIVE DRUGOR A STATIN, FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Novartis AG (CH) | 2003-10-22 | — | — | EP | claimed |
| WO-2002043807-A2 | COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN ANTI-HYPERTENSIVE DRUG OR A STATIN, FOR THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2002-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | REN, AGTR1, AGTR2 | REN 1/4885 |
| US-20040087484-A1 | Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor | AGTR1, HMGCR, AGTR2 | REN 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.